Dupixent® (dupilumab)

BL 761055

Dupixent® (dupilumab)

BL 761055

U.S. License Holder:

Regeneron Pharmaceuticals

Date of License:

March-28-2017

Last Update:

August-15-2019

approved_indications FDA-Approved Indications

DUPIXENT (dupilumab) is an interleukin-4 receptor alpha antagonist indicated:

For the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids;

As an add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma;

As an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).

approved_indications Inter Partes Review Proceedings

PTAB Portal

IPR Case No(s):

IPR2017-01129

U.S. Patent No.
8,679,487 (Anti-interleukin-4 receptor antibodies)

Patent Owner
Immunex Corp.

Petitioner(s)
Genzyme Corp.; Regeneron Pharmaceuticals, Inc.; Sanofi-Aventis US LLC

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Composition of Matter Formulation (Pharmaceutical Composition) Other (Kit)

§ 102 Challenge Instituted
N

§ 103 challenge
N

IPR Status
IPR Not Instituted

IPR2017-01879

U.S. Patent No.
8,679,487 (Anti-interleukin-4 receptor antibodies)

Patent Owner
Immunex Corp.

Petitioner(s)
Aventisub LLC; Genzyme Corp.; Regeneron Pharmaceuticals, Inc.; Sanofi; Sanofi-Aventis US LLC

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Composition of Matter Formulation (Pharmaceutical Composition) Other (Kit)

§ 102 Challenge Instituted
Y

§ 103 challenge
N

Federal Circuit Appeal(s)
19-1777 (condolidated with lead appeal 17-1749)

IPR Status
Final Written Decision (No Instituted Claim Found Unpatentable); Federal Circuit Appeal Pending

IPR2017-01884

U.S. Patent No.
8,679,487 (Anti-interleukin-4 receptor antibodies)

Patent Owner
Immunex Corp.

Petitioner(s)
Aventisub LLC; Genzyme Corp.; Regeneron Pharmaceuticals, Inc.; Sanofi; Sanofi-Aventis US LLC

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Composition of Matter Formulation (Pharmaceutical Composition) Other (Kit)

§ 103 Challenge Instituted
Y

Federal Circuit Appeal(s)
19-1749 (lead appeal, consolidated with 19-1777)

IPR Status
Final Written Decision (All Instituted Claims Found Unpatentable); Federal Circuit Appeal Pending

approved_indications U.S. Patent Litigations

PACER

Case No(s):

1:17-cv-10465 (D. Mass.)

U.S. Patent Nos.
8,679,487 (Anti-Interleukin-4 Receptor Antibodies)

Plaintiffs
Sanofi-Aventis U.S. LLC; Genzyme Corp.; Regeneron Pharmaceuticals, Inc.

Defendants
Amgen Inc.; Immunex Corp.

Status
Dismissed

BPCIA
N

2:17-cv-02613 (C.D. Cal.)

U.S. Patent Nos.
8,679,487 (Anti-Interleukin-4 Receptor Antibodies)

Plaintiffs
Sanofi; Sanofi-Aventis U.S. LLC; Genzyme Corp.; Aventisub LLC; Regeneron Pharmaceuticals, Inc.

Defendants
Immunex Corp.; Amgen Inc. (Interested party)

Status
Case Ongoing

BPCIA
N

related articles Related News Articles

Venable Fitzpatrick’s BiologicsHQ Monthly Injection – April 2019 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. May 7, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – February 2019 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. March 6, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – February 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. March 6, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – August/September 2017 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. October 5, 2017

Methodology

Information contained in the Venable Fitzpatrick BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable Fitzpatrick BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

captcha